NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Predictions

Healthcare > Biotechnology

Buy RARE

*Your capital is at risk

$28.76

-0.270 (-0.93%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

RARE Live board

Community Bull/Bear

Target Next close

Join the RARE prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

RARE Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For RARE

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

RARE Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT ULTRAGENYX PHARMACEUTICAL INC.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	20.46%	Jun 12
DHI $146.71	6.39%	Jun 10
E ETD $20.67	4.79%	Jun 05
EAT $140.46	16.94%	Jun 05
OSW $24.00	17.08%	Jun 04

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by